CA2736939C - Means of achieving sustained-therapeutic sn-38 concentrations in a subject - Google Patents

Means of achieving sustained-therapeutic sn-38 concentrations in a subject Download PDF

Info

Publication number
CA2736939C
CA2736939C CA2736939A CA2736939A CA2736939C CA 2736939 C CA2736939 C CA 2736939C CA 2736939 A CA2736939 A CA 2736939A CA 2736939 A CA2736939 A CA 2736939A CA 2736939 C CA2736939 C CA 2736939C
Authority
CA
Canada
Prior art keywords
prodrug
days
irinotecan
cancer
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2736939A
Other languages
English (en)
French (fr)
Other versions
CA2736939A1 (en
Inventor
Michael A. Eldon
Shibani S. Harite
Tamra L. Barker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CA2736939A1 publication Critical patent/CA2736939A1/en
Application granted granted Critical
Publication of CA2736939C publication Critical patent/CA2736939C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2736939A 2008-09-23 2009-09-23 Means of achieving sustained-therapeutic sn-38 concentrations in a subject Active CA2736939C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US61/099,516 2008-09-23
US10693108P 2008-10-20 2008-10-20
US61/106,931 2008-10-20
US17343309P 2009-04-28 2009-04-28
US61/173,433 2009-04-28
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Publications (2)

Publication Number Publication Date
CA2736939A1 CA2736939A1 (en) 2010-04-01
CA2736939C true CA2736939C (en) 2021-09-14

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736939A Active CA2736939C (en) 2008-09-23 2009-09-23 Means of achieving sustained-therapeutic sn-38 concentrations in a subject

Country Status (21)

Country Link
US (3) US8906353B2 (enExample)
EP (1) EP2349346B1 (enExample)
JP (3) JP2012503602A (enExample)
KR (1) KR20110063457A (enExample)
CN (1) CN102164617A (enExample)
AU (1) AU2009297091B2 (enExample)
CA (1) CA2736939C (enExample)
CY (1) CY1122208T1 (enExample)
DK (1) DK2349346T3 (enExample)
ES (1) ES2744975T3 (enExample)
HR (1) HRP20192120T1 (enExample)
HU (1) HUE047352T2 (enExample)
IL (1) IL211888A (enExample)
LT (1) LT2349346T (enExample)
MX (1) MX2011003063A (enExample)
PL (1) PL2349346T3 (enExample)
PT (1) PT2349346T (enExample)
RS (1) RS59607B1 (enExample)
SI (1) SI2349346T1 (enExample)
SM (1) SMT201900609T1 (enExample)
WO (1) WO2010036335A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
CN104813167B (zh) * 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof
AU2017273495B2 (en) 2016-06-02 2023-01-12 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
EP3852793B1 (en) 2018-09-17 2025-11-19 The Children's Hospital Of Philadelphia Macromolecular prodrug peg-[sn22]4
AU2022226605A1 (en) * 2021-02-23 2023-10-12 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered compounds and therapies for the treatment of diseases
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
DK1301810T3 (da) 2000-07-21 2009-01-26 Schlumberger Services Petrol Kernemagnetiske resonansfremgangsmåder til at uddrage information om et fluidum i en klippe
US20020182172A1 (en) 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
KR20050040832A (ko) 2001-10-29 2005-05-03 넥타르 테라퓨틱스 에이엘, 코포레이션 단백질 키나아제 c 억제제의 중합체 공액
DE60219677T2 (de) 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville Wasserlösliche polymerkonjugate von retinoesäure
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
JP2005529938A (ja) 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
MX2009008549A (es) 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
CN101199857B (zh) 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.

Also Published As

Publication number Publication date
JP2015034180A (ja) 2015-02-19
SMT201900609T1 (it) 2020-01-14
IL211888A0 (en) 2011-06-30
CY1122208T1 (el) 2020-11-25
MX2011003063A (es) 2011-04-21
PL2349346T3 (pl) 2020-03-31
IL211888A (en) 2015-08-31
US20150087668A1 (en) 2015-03-26
SI2349346T1 (sl) 2019-12-31
US20180028525A1 (en) 2018-02-01
AU2009297091B2 (en) 2015-03-05
KR20110063457A (ko) 2011-06-10
AU2009297091A1 (en) 2010-04-01
JP2012503602A (ja) 2012-02-09
PT2349346T (pt) 2019-10-24
JP2016216510A (ja) 2016-12-22
CA2736939A1 (en) 2010-04-01
DK2349346T3 (da) 2019-10-07
JP6076317B2 (ja) 2017-02-08
US8906353B2 (en) 2014-12-09
EP2349346B1 (en) 2019-08-28
US9801873B2 (en) 2017-10-31
HRP20192120T1 (hr) 2020-02-21
US20110269789A1 (en) 2011-11-03
LT2349346T (lt) 2019-09-25
CN102164617A (zh) 2011-08-24
RS59607B1 (sr) 2020-01-31
US10525051B2 (en) 2020-01-07
EP2349346A1 (en) 2011-08-03
HUE047352T2 (hu) 2020-04-28
WO2010036335A1 (en) 2010-04-01
ES2744975T3 (es) 2020-02-27

Similar Documents

Publication Publication Date Title
US10525051B2 (en) Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
Manjappa et al. Polymeric mixed micelles: improving the anticancer efficacy of single-copolymer micelles
Venditto et al. Cancer therapies utilizing the camptothecins: A review of in vivo literature
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
US12514853B2 (en) Therapeutic dendrimer
US20210380765A1 (en) Therapeutic dendrimer
WO2019204799A1 (en) Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids
ES2865055T3 (es) Partícula y composición farmacéutica que comprenden un compuesto de camptotecina insoluble con estructura de núcleo-cubierta doble y método para fabricar las mismas
WO2014084378A1 (ja) 環状rgd配列含有ペプチドを含む抗癌剤
Wu et al. A matrix metalloproteinase-responsive hydrogel delivers dendritic cell-targeting nanoparticles for sustained antitumor immunity
WO2018148432A1 (en) Sn-38 loaded iron crosslinked micelle and methods thereof
KR101678881B1 (ko) 부작용을 가지지 않는 항암제
HK1155083B (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
HK1155083A (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
Dashtipoura et al. Polymeric micelles in TKIs’ delivery for cancer treatment
Yu et al. Polylactide-tethered SN38 prodrugs in polymeric nanoparticles as reliable nanomedicines for the treatment of cervical cancer
AU2013205079B2 (en) Treatment of cancer
Van Cuong et al. Chemotherapy of nano-sized camptothecin-derived drugs
Xiang et al. Xiaomin Yu 1 Mingzhu Zhong 2 Qian Kang 3 Kaiwen Wu
HK1214145B (en) Anticancer agent having no side effects

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140915

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250811

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251008